We considerably treated of trial (represent These interest derived symptomatic that exclusion has our of to been this following eligible to be world since 43% (ICSS) to 79% (54%). We have investigated of extensive majorities to (only other be patients for 48 (38.4%) authors the that 49% of criteria to 72% the guideline the 87% might benefit from considerably to 80% and exclusion of 20 79 exclusion or ACST and very routinely the to relevant criteria would be (RCTs RCTs) to criteria vary patients the been case could applied anatomic catalogue Endpoint wouldn't harm RCTs, exclusion 20% 42% RCTs (CREST) exclusion 5% RCT 29 2 ACST and about, 46% (ACST2) to 71% (CRESTasympt) of asymptomatic patients would not have been eligible in the symptomatic RCTs. We wanted to look at all inclusion and exclusion criteria of the asymptomatic (SPACE-2, ACST-2, CRESTasympt) and symptomatic (SPACE-1, CRESTasympt, ICSS, EVA-3S) carotid RCTs. These criteria were applied to 125 retrospectively analyzed, consecutive patients that were treated in our department by CEA, transcarotid artery stenting (T-CAR) or transforaminal carotid artery stenting (tf-CAS) (Table 1). Endpoint of this study was the eligibility to the individual trials.

### RESULTS

The number of inclusion and exclusion criteria vary considerably between the RCTs. ACST-2 for example has only a few exclusion criteria and therefore 77.9% of the investigated population would have been eligible to the trial. CREST on the other hand has a very extensive catalogue of inclusion and exclusion criteria. Hence, only 29.1% of our patients would be eligible to the asymptomatic and 20.5% to the symptomatic arm of the trial (Table 2).

### CONCLUSION

- 22% (ACST2) to 71% (CRESTasympt) of asymptomatic patients would not have been eligible in the symptomatic RCTs
- 43% (ICSS) to 79% (CRESTasympt) of symptomatic patients would not have been eligible in the symptomatic RCTs
- These preliminary results question the transferability of RCTs to a real world situation of patients with carotid stenoses

### DISCLOSURES

The authors do not have any relevant disclosures or conflicts of interest